Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (May 2021)
28 slides from Orion Oyj Class A's investor day presentation, May 26, 2021
Slide 1: Creating value through Research & Development
Creating value through Research & Development Professor Outi Vaarala, MD, PhD Senior Vice President, Research & Development
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: SVP R&D Orion from June 2020
SVP R&D Orion from June 2020 MD, PhD (immunology), University of Helsinki Professor of Immunology, LiU, Sweden, 2001 Research Professor, THL, 2004-2014 EMA Permanent External Expert 2005-2014 VP Research, AZ/Medimmune 2014-2019 VP Oncology Research Orion 2019-2020 Orion Corporation Capital Markets D
Slide 4: Agenda
Agenda 1. RD renewal 2. Research focus areas 3. Clinical pipeline Orion Corporation Capital Markets Day 26 May 2021 4
Slide 5: Renewal of Orion R&D
Renewal of Orion R&D Building well-being
Slide 6: Renewal of Orion R&D – starting point
1. Re-newal of Orion R&D – starting point STRENGHTS AREAS TO DEVELOP Build a balanced pipeline with Hormonal cancer drug discovery continuous feed of clinical projects Parkinson’s disease drug discovery Increase success rate and speed ALS Ph3 program in neurological rare diseases area Science & Data
Slide 7: We follow the patient's journey and transform science into life-changing medicines
We follow the patient’s journey and transform science into life-changing medicines Non-metastatic Metastatic Prostate nmHSPC1 mHSPC3 nmCRPC2 mCRPC4 Cancer Adjuvant Chemo Combo No Chemo Combo Disease Disease Targeted Target Intelligent subtypes drivers drugs patients trials Success Focus Speed 1) nmH
Slide 8: Key changes in Orion R&D
Key changes in Orion R&D 1 Research strengthened 3 Focused clinical trials 5 Boosting generics development to drive target on biomarker identification selected and validation patients 4 6 Microbiome 2 Resources re- allocated for the prioritised 4 Support pipeline with in-licensing and research in An
Slide 9: Research focus areas
Research focus areas GRION Building well-being
Slide 10: Research Areas in Orion's R&D
Research Areas in Orion’s R&D Neurological Disorders Oncology Research Discovery Sciences • Pain • Immuno-oncology • New Therapies • Neurodegenerative • Cancer Genomics and • Microbiome Proteinopathy Signalling • Discovery Technologies • Neurological Genetic • Antibody Drug Conjugates Disorders Orio
Slide 11: Neurological Disorders Research
Neurological Disorders Research Research Areas Pain - Ion channels and Ion channel Impaired neuro-immune interaction pathology protein homeostasis Neurodegenerative Proteinopathy - Pathological Fermion protein aggregation and clearance • APIs to Orion’s proprietary products Lysosomal Neurological Ge
Slide 12: Oncology Research
Oncology Research Research Areas Immuno-Oncology • FiCAR T-cell therapy FiCAR T-cell therapy DNA Repair • 2nd generation immune- checkpoint inhibitors Cancer genomics and Fermion Cell signalling • APIs to Orion’s proprietary products • Generic Cell APIs signalling • Contract development Antibody dru
Slide 13: Discovery Sciences
Discovery Sciences Research Areas New Therapies • Cell and Gene Therapy FiCAR T-cell therapy Microbiome Microbiome Fermion • APIs to Orion’s proprietary products • Generic APIs Discovery Technologies • Contract development for pharmaceutical companies Orion Corporation Capital Markets Day 26 May 202
Slide 14: CAR T-cell therapy research project with The Finnish Red Cross
We have initiated CAR T-cell therapy research project in collaboration with The Finnish Red Cross Orion Corporation Capital Markets Day 26 May 2021 14
Slide 15: R&D research pipeline in May 2021
R&D research pipeline in May 2021 2021 2022 2023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Several tumor types Small molecule Hematological/ solid later Cell therapy Pain Small molecule Several tumor types Large molecule/ADC Several tumor types Small molecule Several tumor types Small molecule Several tumor type
Slide 16: Key clinical pipeline
Key clinical pipeline
Slide 17: Key clinical development pipeline
Key clinical development pipeline Phase completed Phase ongoing Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 Prostate
Slide 18: Nubeqa: Clinical trials ongoing to expand indication to mHSPC
Nubeqa®: Clinical trials ongoing to expand indication to patients with metastatic hormone sensitive prostate cancer We follow the Patient’s Journey Non-metastatic Metastatic nmHSPC1 mHSPC3 Prostate Cancer nmCRPC2 mCRPC4 Adjuvant Chemo Combo No Chemo Combo DASL-HiCaP approved ARASENS ARANOTE enzaluta
Slide 19: ARASENS & ARANOTE trials aiming to expand darolutamide indication
ARASENS & ARANOTE trials aiming to expand the indication of darolutamide to metastatic hormone-sensitive prostate cancer Target Trial on-going Treatment Combo Primary End-point Present Status Patients Darolutamide + ADT + ARASENS mHSPC Overall survival Fully recruited Docetaxel Radiological Recruitm
Slide 20: Key clinical development pipeline
Key clinical development pipeline Phase completed Phase ongoing Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 Prostate
Slide 21: CYP11A1 inhibitors (ODM-208 & ODM-209) to treat mCRPC
CYP11A1 inhibitors (ODM-208 & ODM-209) to treat the patients with metastatic castration-resistant prostate cancer (mCRPC) We follow the Patient’s Journey Non-metastatic Metastatic nmHSPC1 mHSPC3 Prostate Cancer nmCRPC2 mCRPC4 Adjuvant Chemo Combo No Chemo Combo ODM-208/ DASL-HiCaP approved ARASENS A
Slide 22: ODM-208 (& ODM-209): CYP11A1 inhibitor to treat mCRPC
ODM-208 (& ODM-209): CYP11A1 inhibitor to treat the patients with metastatic castration-resistant prostate cancer (mCRPC) ODM-208 Target Patients Target patients with prostate cancer that has become resistant to the standard hormonal treatments. ● First–in–class oral molecule to Potential indication
Slide 23: ODM-208 reduces the serum steroids below the detection limit in mCRPC patients
ODM-208 reduces the serum steroids below the detection limit in the patients with mCRPC and ongoing ADT Steroid decrease in three patients dosed in CYPIDES Ph1 PSA decrease in two responders Orion Corporation Capital Markets Day 26 May 2021 23
Slide 24: CYPIDES and STESIDES studies to select the best molecule
CYPIDES and STESIDES studies to select the best molecule for the patients with metastatic castrate-resistant prostate cancer (progressed during one or more novel hormonal therapy and chemotherapy) Target Trial on-going Treatment Primary end-point Present Status Patients ODM-208 + Safety glucocortico
Slide 25: Key clinical development pipeline
Key clinical development pipeline Phase completed Phase ongoing Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 Prostate
Slide 26: Patient centric portfolio for Asthma & COPD
Patient centric portfolio for Asthma & COPD Current portfolio S A LME T E R OL / B U D E S O N ID E / SALBUTAMO L FO R MO T E R O L B U D E S O N ID E BECLOMETAS ONE FLU T IC A S ON E FO R MO T E R O L Clinical development projects aiming to expand the offering Indacaterol-glycopyrronium Tiotropium
Slide 27: Main Orion Animal Health Marketing Authorisations
Main Orion Animal Health Marketing Authorisations Geepenil Comforion Benzorion Kefavet A novel alpha-2 adrenoceptor agonist, alleviates acute anxiety and fear associated In registration phase with travel and separation anxiety in dogs Several activities in microbiome field - different species such a
Slide 28: Orion Corporation Capital Markets Day
Orion Corporation Capital Markets Day